The following are the main types of medication for the treatment of direct spinal disease:
I. Inflammatory drugs (NSAIDs)
1. Mechanisms for functioning
– These drugs are used to combat inflammation, pain, deheating and to reduce joint swelling, mainly by inhibiting the activity of the cyclic oxide enzyme (COX) and reducing prostate synthesis.
Common drugs and characteristics
– Broven:
– Relatively common, with a function of decomposition, pain and inflammation. The average adult use rate is 0.3 – 0.6 g per day, 3 – 4 times a day. The adverse effects are relatively light, and may be gastrointestinal disorders, such as nausea, vomiting, indigestion, etc.
– Dichlorphenic acid:
– Anti-inflammation, pain relief. There are various types of agents, such as tablets, capsules, embolisms, etc. Orals are generally 25 – 50 mg/day, 2 – 3 times per day. Gastrointestinal irritation may occur during use, and a small number of patients may be allergic.
– Cyclops:
– Selective COX-2 inhibitor, relatively small irritation of the gastrointestinal tract. The usual usage is 0.2 g/day, 1 – 2 times a day. However, long-term use may increase the risk of cardiovascular malfeasance and should be used with caution by patients with a history of cardiovascular disease.
II. PROBLEMS (DMARDs)
1. Mechanisms for functioning
– These drugs can improve the progress of patients with direct spinal diseases and inhibit their own immune response.
Common drugs and characteristics
– Nitrogen sulfur:
– Have some effect on direct spinal disease, especially for patients suffering from stress on their outer necks. The general start-up dose is 0.25 g per day, with an increase of 0.25 g per week thereafter, up to 1 – 3 g per day and 2 – 3 times. The adverse effects include gastrointestinal reaction, rashes, liver damage, bone marrow inhibition, etc., and regular examination of blood routines and liver function in the course of drug use.
– Mecha butterflies:
– It is often used for the treatment of rheumatism, which also has some effect on acoustic spinal column, especially for patients who are associated with external arthritis or eye inflammation. In general, 7.5 – 15 milligrams per week, one oral. The adverse effects are gastrointestinal reaction, oral ulcer, liver damage, bone marrow inhibition, etc., and use with close monitoring of blood protocol, liver function and kidney function.
III. Biological agents
1. Mechanisms for functioning
– Biological agents are primarily targeted at specific inflammatory causes, such as tumour cause of death – alpha (TNF-α), white cell meds – 17A (IL-17A), which effectively control inflammation, mitigate symptoms and slow progress.
Common drugs and characteristics
– Cause of death from cancer.
– Adamu stand alone:
– 40 milligrams per 2 week. The risk of infection, such as tuberculosis infection, may be increased during use, and relevant tests, such as tuberculosis screening, are required prior to use.
– Inaseep:
– Two injections per week with 25 milligrams. Injection-related responses, such as swelling, pain, etc., may occur, and there is a risk of infection.
– White cellulose – 17A constraint:
– Sicchio fights:
– The initial dose was 150 mg per week for the weeks 0, 1, 2 and 3, followed by 150 mg per month. Common adverse effects include upper respiratory infections, nasal inflammation, etc.
IV. Sugar cortex hormones
1. Mechanisms for functioning
– Strong anti-inflammation and immunosuppressive effects, which can rapidly mitigate the symptoms of people suffering from acute spinal disease, especially during acute onset.
2. Principles of use
– The long-term and extensive use of sugar-coated hormones is not generally advocated. Partial or short-term use is possible in cases of acute eye inflammation, severe exterior arthritis, etc. For example, acute iris can be treated with a local drop-in of Poneysoon drop-out fluid; in cases of acute exterior ecstasy, a small oral dose of Poneysone (generally no more than 10 mg/day) should be reduced as soon as the symptoms are mitigated.
The use of medicines for patients with direct spina syndrome needs to be conducted under the professional guidance of a doctor, who will develop a personalized drug programme based on a combination of the patient ‘ s specific medical condition, physical condition, and complications.
